Preventing Type 1 Diabetes with a Groundbreaking Vaccine
Preventive Vaccine
Innovative Science, Proven Results
Our preventive vaccine, PRV-101, leverages proven and safe technology similar to established vaccines like polio and enterovirus 71 vaccines. Preclinical studies have demonstrated PRV-101’s ability to induce strong neutralizing antibody responses without safety concerns. Recently, our vaccine successfully completed a Phase 1 human trial (ClinicalTrials.gov Identifier: NCT04690426), showing excellent safety, tolerability, and immune response profiles.
Vactech’s vaccine addresses significant unmet medical needs, benefiting large target populations—particularly those genetically predisposed to type 1 diabetes (approximately 20% of the Caucasian population)—and individuals vulnerable to acute Coxsackievirus infections. Its patented composition positions PRV-101 as the potential first-to-market preventive vaccine for type 1 diabetes, supported by a strong pipeline of related vaccines, antivirals, and diagnostics.
“Vactech’s impressive track record and strategic collaborations with leading pharmaceutical companies, biotech industry partners, and academic institutions have positioned the company at the forefront of preventive solutions for type 1 diabetes. These collaborations have been instrumental in advancing vaccine candidates into clinical trials. With its innovative approach and strong global partnerships, Vactech clearly stands out as a global leader in the prevention of type 1 diabetes and related conditions.” Petri Laine - Partner, Innovestor Venture Capital
PRV-101: New video explains a novel approach to preventing type 1 diabetes
Vactech’s new video highlights the scientific rationale behind its PRV-101 vaccine candidate and how blocking Coxsackie B virus infections could help reduce the risk of type 1 diabetes. It outlines the evidence linking these viruses to disease onset and explains the vaccine’s mechanism in building a durable, preventive immune response.